Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials

被引：14
作者：
Foo, Joo-Pin [1 ]
Mantzoros, Christos S. [1 ,2 ]
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab,Dept Internal Med, Boston, MA 02215 USA
[2] Harvard Univ, Dept Internal Med, Sch Med, VA Boston Healthcare Syst,Sect Endocrinol, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2012年 / 61卷 / 10期
关键词：
ACTIVE ANTIRETROVIRAL THERAPY; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; REVERSES INSULIN-RESISTANCE; VIRUS-INFECTED PATIENTS; RECOMBINANT HUMAN LEPTIN; HORMONE-RELEASING FACTOR; MYOCARDIAL-INFARCTION; PROTEASE-INHIBITOR; DOUBLE-BLIND; REPLACEMENT THERAPY;
D O I：
10.1016/j.metabol.2012.04.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1331 / 1336
页数：6
相关论文
共 65 条
  • [1] Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy
    Addy, CL
    Gavrila, A
    Tsiodras, S
    Brodovicz, K
    Karchmer, AW
    Mantzoros, CS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02) : 627 - 636
  • [2] Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
    Arioglu, E
    Duncan-Morin, J
    Sebring, N
    Rother, KI
    Gottlieb, N
    Lieberman, J
    Herion, D
    Kleiner, DE
    Reynolds, J
    Premkumar, A
    Sumner, AE
    Hoofnagle, J
    Reitman, ML
    Taylor, SI
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) : 263 - 274
  • [3] Site and mechanism of leptin action in a rodent form of congenital lipodystrophy
    Asilmaz, E
    Cohen, P
    Miyazaki, M
    Dobrzyn, P
    Ueki, K
    Fayzikhodjaeva, G
    Soukas, AA
    Kahn, CR
    Ntambi, JM
    Socci, ND
    Friedman, JM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (03) : 414 - 424
  • [4] HIV and metabolic syndrome - A comparison with the general population
    Bonfanti, Paolo
    Giannattasio, Cristina
    Ricci, Elena
    Facchetti, Rita
    Rosella, Elena
    Franzetti, Marzia
    Cordier, Laura
    Pusterla, Luigi
    Bombelli, Michele
    Sega, Roberto
    Quirino, Tiziana
    Mancia, Giuseppe
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (04) : 426 - 431
  • [5] Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management
    Calza, L
    Manfredi, R
    Chiodo, F
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (02) : 89 - 99
  • [6] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [7] No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
    Carr, A
    Workman, C
    Carey, D
    Rogers, G
    Martin, A
    Baker, D
    Wand, H
    Law, M
    Samaras, K
    Emery, S
    Cooper, DA
    [J]. LANCET, 2004, 363 (9407) : 429 - 438
  • [8] Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
    Carr, A
    Samaras, K
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1998, 351 (9119) : 1881 - 1883
  • [9] A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy
    Cavalcanti, Rodrigo B.
    Raboud, Janet
    Shen, Sandy
    Kain, Kevin C.
    Cheung, Angela
    Walmsley, Sharon
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (12) : 1754 - 1761
  • [10] Abacavir and cardiovascular risk: Reviewing the evidence
    Costagliola D.
    Lang S.
    Mary-Krause M.
    Boccara F.
    [J]. Current HIV/AIDS Reports, 2010, 7 (3) : 127 - 133
1234567